The bottom line is that Celgene plans to replace Revlimid, but not with just one drug. Instead, Alles pointed to four hematology drugs in Celgene's pipeline that he thinks will take the baton from Revlimid and become blockbuster franchises.
Does Celgene plan on just breaking down Revlimid into four different drugs to max out profits? that seems what it looks like to me.
Revlimid ranked as the second best-selling drug in the world last year, with sales of nearly $8.2 billion. Market research company EvaluatePharma predicts that the drug will slip one spot by 2024 but will rake in around $11.9 billion.
I think that it should not be ranked on the amount of sales becuase as we have seen Revlimid price is outrageous so than can be a ton of different drugs that sell way more products but they are just cheaper.
Amgen (NASDAQ:AMGN) released exciting data from a handful of patients that suggests it's found a much easier way to achieve the same goal.
Amgen has found a way around celgene and said to be much easier. but how will celgene react?
At a recent scientific conference, Amgen shared preliminary data from five patients with multiple myeloma so aggressive that their disease didn't back down after four to six previous lines of treatment. Eliciting minor responses from just a couple would be impressive, but AMG-420 went way beyond and helped five patients treated with a higher dosage achieve complete remission.
showing data just from 5 people you chose is very bias.
"The gaming that I see is where people are blocking generic entry by restricting access to the doses," Gottlieb said Tuesday. "It's a pervasive problem."
it is sad that it can be called a game. Celgene is literally playing God by deciding who can live by charging so much.
"They're building these protections around the drugs so if a company comes in and tries to do a generic, even with an old drug, they're going to have a very hard time,"
If it is obvious that the company is creating roadblocks for other companies so that they can continue to hold a monopoly should be illegal
A few years after Thalomid hit the market, Celgene altered it a bit by removing an oxygen atom and adding a nitrogen atom, creating a new amino group. The company called the new drug Revlimid.
it seems very fishy that one drug can cure soo many different things, even with very little changes. I am surprised that the FDA allowed Celgene to release Thalomid again.
"The issue is how long does that monopoly last,"
an company should not be able to hold a monopoly and if it does it should be regulated by the government which it seems it has not been regulated enough in this case.
"They exploit loopholes in our system to delay generic entry. In these ways, they extend a drug's monopoly beyond what Congress intended."
the system created to help drug companies become competitive and hold the right to the drug for a little has been abused to just bring in max profits as celgene has done.
Celgene has kept generic competition at bay by constructing an almost impenetrable fortress of patents and grants of market exclusivity around Revlimid, and its sister drug Thalomid, while also taking steps to ensure that generic competitors can't get their hands on enough of the drugs to develop viable alternatives.
It seems as if Celgene is more worried about profits than doing what benefits the majority
By the time David Mitchell started taking Revlimid in November 2010, Celgene had bumped the price up to about $8,000 a month. When he took his last month's worth of pills in April 2016, the sticker price had reached $10,691. By last March, the list price had reached $16,691.
The price of Celgene Has increased from 6,195 to 16,691, it has been able to do so because of no competition.